HK Stock Market Move | IMMUNEONCO-B(01541) rose more than 15% during trading hours. The institution stated that the company is about to release the world's first clinical data on macrophage cell therapy for treating SLE.

IMMUNEONCO-B (01541) rose more than 15% during trading hours, as of the time of publication, it had risen by 14.15% to 9.36 Hong Kong dollars, with a trading volume of 71.9753 million Hong Kong dollars. Huachuang Securities recently released a research report stating that IMM0306's treatment for SLE completed its Phase Ib trial in October 2024 with the first dose administered, and is expected to report the world's first clinical data of macrophage cell therapy for treating SLE by mid-2025, moving into Phase II. It is expected that the company will submit an IND to the United States in the second half of 2025 to expand its global market. The treatment for NMOSD with IMM0306 has started its Phase Ib clinical trial and is expected to move into Phase III by mid-2026; the treatment for LN is expected to start its Phase II clinical trial by the end of 2025 or 2026. Guoyuan International stated that Yiming Angke signed an authorization and cooperation agreement with InstilBio in August 2024, granting exclusive rights for research, development, and commercialization of IMM2510 and IMM27M outside of Greater China. The company will receive an upfront payment and near-term payments totaling up to 50 million US dollars, as well as milestone payments of up to 2.1 billion US dollars. They will also receive a royalty fee calculated as a single to low double-digit percentage of global net sales. IgG1Fc can activate ADCC, and the enhanced ADCC antibodies aim to induce direct killing of immune-suppressed PD-L1+ tumor cells. Although there is fierce competition in the VEGF/PD-(L)1 bispecific antibody market, the company's structural design advantages are apparent, and they are expected to achieve superior therapeutic effects. The Phase Ib/II clinical trial for non-small cell lung cancer has already commenced in China.